CA-224 5mg 5mg | Purity Not Available
Adooq Bioscience
CA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
More Information Supplier PageCA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
More Information Supplier PageCA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
More Information Supplier PageCA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
More Information Supplier PageASP9521 is a novel, selective, orally bioavailable inhibitor of 17??-hydroxysteroid dehydrogenase type 5 (17bHSD5, AKR1C3).
More Information Supplier PageASP9521 is a novel, selective, orally bioavailable inhibitor of 17??-hydroxysteroid dehydrogenase type 5 (17bHSD5, AKR1C3).
More Information Supplier PageASP9521 is a novel, selective, orally bioavailable inhibitor of 17??-hydroxysteroid dehydrogenase type 5 (17bHSD5, AKR1C3).
More Information Supplier PageGilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
More Information Supplier PageGilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
More Information Supplier PageGilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.
More Information Supplier PageCF-102 is an orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist with potential antineoplastic activity.
More Information Supplier Page